At Repligen bioprocessing seminars, thought leaders and professionals from around the world meet and review exciting new drivers of bioprocessing efficiency, learn from adopters of transformative technologies, evaluate risk landscapes and collaborate to help set the standards for modern bioproduction. 


To view speaker biographies and session abstracts,
click Expand All or the + next to each title.

Registration will begin at 9:00 a.m. Pre-registration is required to attend.


Downstream process development for monoclonal antibodies (mAbs) has become an exercise in efficiency due to the desire to be fast-to-clinic. Many companies have resorted to using a purification platform to decrease timelines. With the onset of high-throughput process development, development timelines and material requirements could be further decreased. Here, we demonstrate the synergy of utilizing high-throughput development with an existing downstream platform to enable mAb drug candidates to be brought to clinical trials faster. Using pre-determined and antibody-compatible parameters, a lean phase 1 downstream process was developed. Final conditions were determined based on maximum process yield and aggregate clearance. This study also served to show the comparability between microliter-scale (Tecan with RoboColumns®) and milliliter-scale (AKTA® with small-scale columns) development.


There is no charge for attendance but registration is required. Seats are limited to end-users of bioprocessing tools and technologies.

Travel, accommodations, and incidental expenses are the responsibility of attendees. Lunch  will be served.

Le Meridien Hotel

Hunsaker Ballroom
20 Sidney Street
Cambridge, MA, 02139



Scroll To Top